시장보고서
상품코드
1132594

세계의 HLA 타이핑 시장 : 제품 유형별(기기, 소프트웨어), 기술별(분자 : PCR, 시퀀싱/혈청), 용도별(진단, 연구), 최종사용자별, 지역별 예측(-2029년)

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing ], Serology), Application (Diagnostics, Research), End User, and Geography - Forecast to 2029

발행일: | 리서치사: Meticulous Market Research Pvt. Ltd. | 페이지 정보: 영문 233 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 HLA 타이핑 시장 규모는 2022-2029년 5.6%의 CAGR로 성장하며, 2029년에는 19억 달러에 달할 것으로 예측되고 있습니다. 시장의 성장을 지원하는 주요 요인으로는 장기 이식의 증가, HLA 타이핑에 사용되는 분자 어세이의 기술적 진보, 장기 제공에 관한 사람들의 의식 향상 등을 들 수 있습니다.

세계의 HLA 타이핑 시장을 조사했으며, 시장의 개요, 시장 규모 및 예측, 동향, 촉진요인·억제요인, 경쟁 구도, 제품 유형별·기술별·용도별·최종사용자별·지역별 분석 및 기업 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

  • 시장의 정의
  • 시장 에코시스템
  • 통화
  • 주요 이해관계자

제2장 조사 방법

  • 조사 프로세스
  • 데이터 수집과 검증
    • 2차 조사
    • 1차 조사
  • 시장 평가
    • 시장 규모 예측
    • 시장 점유율 분석
  • 조사의 전제조건
  • 조사의 제한

제3장 주요 요약

제4장 시장 인사이트

  • 서론
  • 촉진요인
    • 장기 이식의 증가
    • HLA 타이핑의 기술적 진보
  • 억제요인
    • HLA 타이핑에 필요한 기기의 고비용
  • 기회
    • 장기 제공의 중요성에 관한 인식의 향상
  • 과제
    • 장기 기증자와 장기 수용자의 갭
  • COVID-19의 영향 분석

제5장 세계의 HLA 타이핑 시장 : 제품별

  • 서론
  • 소모품
  • 기기
  • 소프트웨어·서비스

제6장 세계의 HLA 타이핑 시장 : 기술별

  • 서론
  • 분자 기술
    • PCR 기반 분자 기술
    • 시퀀싱 기반 분자 기술
    • DNA 마이크로어레이
  • 비분자 기술

제7장 세계의 HLA 타이핑 시장 : 용도별

  • 서론
  • 진단
    • 도너와 수취인 크로스 매칭
    • 수혈 요법
    • 기타
  • 연구

제8장 세계의 HLA 타이핑 시장 : 최종사용자별

  • 서론
  • 진단 연구소
  • 병원·이식 센터
  • 학술·연구기관

제9장 HLA 타이핑 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동·아프리카

제10장 경쟁 구도

  • 서론
  • 주요 성장 전략
  • 경쟁 벤치마킹

제11장 기업 개요(사업 개요, 재무 스냅숏, 제품 벤치마킹 및 전략적 개발)

  • Becton, Dickinson and Company(BD)
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina Inc.
  • CareDx, Inc.
  • Genome Diagnostics B.V.(GenDx)
  • TBG Diagnostics Limited(TDL)
  • BAG Diagnostics GmbH
  • Omixon Inc.
  • Luminex Corporation
  • inno-train Diagnostik GmbH
  • Pacific Biosciences of California, Inc.
  • Fujirebio Holdings, Inc.

제12장 부록

KSA 22.10.20

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease], Research), End User, and Geography - Global Forecast to 2029

The Global HLA Typing Market is expected to grow at a CAGR of 5.6% from 2022 to 2029 to reach $1.90 billion by 2029.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the HLA typing market is attributed to the increasing number of organ transplants and technological advancements in the molecular assays used for HLA typing. In addition, the increasing awareness amongst people regarding organ donations offers a growth opportunity for the HLA typing market.

Based on product, in 2022, the consumables segment is estimated to account for the largest share of the HLA typing market. High demand for consumables, availability of diverse consumables, and companies focused on launching new HLA typing consumables contribute to the growth of this segment. For instance, in 2020, Omixon Inc. (U.S.) launched an 11-locus multiplex HLA genotyping assay.

Based on technology, in 2022, the molecular technologies segment is estimated to account for the largest share of the HLA typing market. Advancements and benefits of molecular technologies compared to non-molecular technologies contribute to the large share of this segment.

Based on application, in 2022, the diagnostics segment is expected to account for the largest share of the HLA typing market. The high prevalence of chronic and metabolic diseases leading to organ failures is responsible for the largest segment share. The application of HLA typing for donor-recipient cross-matching, infectious disease pathogenesis, and transfusion is rising, contributing to the largest segment share.

Based on end user, in 2022, the diagnostic laboratories segment is estimated to account for the largest share of the HLA typing market. HLA typing products are frequently used in diagnostics laboratories for disease diagnosis and donor-recipient cross-matching. Outsourcing laboratory services by hospitals and transplant centers and consolidating diagnostics laboratories contribute to the large share of this segment. The partnerships or outsourcing of laboratory services provides benefits such as cost savings, efficiency gains, and the right allocation of resources. Thus, the increasing collaboration between hospitals/transplant centers with diagnostic laboratories results in adoption of HLA typing products by diagnostic laboratories.

An in-depth analysis of the geographical scenario of the HLA typing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is estimated to account for the largest share of the HLA typing market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The highest number of organ transplants, high prevalence of chronic diseases, high spending on healthcare, and well-established healthcare infrastructure are the primary factors responsible for the large share of the North American HLA typing market.

Some of the key players operating in the global HLA typing market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Genome Diagnostics B.V. (GenDx) (Netherlands), Illumina, Inc. (U.S.), CareDx (U.S.), Immucor Inc. (U.S.), TBG Diagnostics Limited (Australia), BAG Diagnostic GmbH (Germany), Omixon Inc. (Hungary), Luminex Corporation (U.S.), inno-train Diagnostik GmbH (Germany), Pacific Biosciences of California, Inc. (U.S.), and Fujirebio Holdings, Inc. (Japan).

Scope of the Report:

HLA Typing Market, by Product

  • Consumables
  • Instruments
  • Software & Services

HLA Typing Market, by Technology

  • Molecular Technologies
  • PCR-based Molecular Techniques
    • Sequence-specific Primers
    • Sequence-specific Oligonucleotide
    • Other PCR-based Molecular Techniques

Other PCR-based molecular techniques include RPLF-PCR, SNP-PCR, and PCR-SSCP.

  • Sequencing-based Molecular Technologies
    • Sangers Sequencing
    • Next-generation Sequencing
    • Pyrosequencing
  • DNA Microarray
  • Non-molecular Technologies

HLA Typing Market, by Application

  • Diagnostics
  • Donor Recipient Cross-matching
  • Transfusion Therapy
  • Other Diagnostic Applications

Other diagnostic applications include Autoimmune Disease Diagnosis, Cancer Diagnosis, Infectious Disease Testing and Paternity testing.

  • Research

HLA Typing Market, by End Users

  • Diagnostics Laboratories
  • Hospitals & Transplant Centers
  • Academic & Research Institutes

HLA Typing Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLA)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-up Approach
      • 2.3.1.2. Top-down Approach
      • 2.3.1.3. Growth forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Increasing Number of organ Transplants
    • 4.2.2. Technological Advancements in HLA Typing
  • 4.3. Restraints
    • 4.3.1. High Cost of Instruments Required to HLA Typing
  • 4.4. Opportunities
    • 4.4.1. Increasing Awareness Regarding the Importance of Organ Donations
  • 4.5. Challenges
    • 4.5.1. Gap Between Organ Donations and Organ Receivers
  • 4.6. Impact Analysis of COVID-19

5. Global HLA Typing Market, by Product

  • 5.1. Introduction
  • 5.2. Consumables
  • 5.3. Instruments
  • 5.4. Software & Services

6. Global HLA Typing Market, by Technology

  • 6.1. Introduction
  • 6.2. Molecular Technologies
    • 6.2.1. PCR-based Molecular Techniques
      • 6.2.1.1. Sequence-specific Primers
      • 6.2.1.2. Sequence-specific Oligonucleotide
      • 6.2.1.3. Other PCR-based Molecular Techniques
    • 6.2.2. Sequencing-based Molecular Technologies
      • 6.2.2.1. Sangers Sequencing
      • 6.2.2.2. Next-generation Sequencing
      • 6.2.2.3. Pyrosequencing
    • 6.2.3. DNA Microarray
  • 6.3. Non-molecular Technologies

7. Global HLA Typing Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostics
    • 7.2.1. Donor Recipient Cross-Matching
    • 7.2.2. Transfusion Therapy
    • 7.2.3. Other Diagnostic Applications
  • 7.3. Research

8. Global HLA Typing Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostics Laboratories
  • 8.3. Hospitals & Transplant Centers
  • 8.4. Academic & Research Institutes

9. HLA Typing Market, by Geography

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. U.K.
    • 9.3.3. France
    • 9.3.4. Spain
    • 9.3.5. Italy
    • 9.3.6. Rest of Europe (RoE)
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest of Asia-Pacific (RoAPAC)
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America (RoLA)
  • 9.6. Middle East & Africa

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking

11. Company Profiles (Business Overview, Financial Snapshot, Product Benchmarking, and Strategic Developments)

  • 11.1. Becton, Dickinson and Company (BD)
  • 11.2. Bio-Rad Laboratories, Inc.
  • 11.3. Thermo Fisher Scientific Inc.
  • 11.4. QIAGEN N.V.
  • 11.5. Illumina Inc.
  • 11.6. CareDx, Inc.
  • 11.7. Genome Diagnostics B.V. (GenDx)
  • 11.8. TBG Diagnostics Limited (TDL)
  • 11.9. BAG Diagnostics GmbH
  • 11.10. Omixon Inc.
  • 11.11. Luminex Corporation
  • 11.12. inno-train Diagnostik GmbH
  • 11.13. Pacific Biosciences of California, Inc.
  • 11.14. Fujirebio Holdings, Inc.

12. Appendix

  • 12.1. Questionnaire
  • 12.2. Available Customization
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제